Back to Search Start Over

Reversal of viral and epigenetic HLA class I repression in Merkel cell carcinoma.

Authors :
Lee PC
Klaeger S
Le PM
Korthauer K
Cheng J
Ananthapadmanabhan V
Frost TC
Stevens JD
Wong AY
Iorgulescu JB
Tarren AY
Chea VA
Carulli IP
Lemvigh CK
Pedersen CB
Gartin AK
Sarkizova S
Wright KT
Li LW
Nomburg J
Li S
Huang T
Liu X
Pomerance L
Doherty LM
Apffel AM
Wallace LJ
Rachimi S
Felt KD
Wolff JO
Witten E
Zhang W
Neuberg D
Lane WJ
Zhang G
Olsen LR
Thakuria M
Rodig SJ
Clauser KR
Starrett GJ
Doench JG
Buhrlage SJ
Carr SA
DeCaprio JA
Wu CJ
Keskin DB
Source :
The Journal of clinical investigation [J Clin Invest] 2022 Jul 01; Vol. 132 (13).
Publication Year :
2022

Abstract

Cancers avoid immune surveillance through an array of mechanisms, including perturbation of HLA class I antigen presentation. Merkel cell carcinoma (MCC) is an aggressive, HLA-I-low, neuroendocrine carcinoma of the skin often caused by the Merkel cell polyomavirus (MCPyV). Through the characterization of 11 newly generated MCC patient-derived cell lines, we identified transcriptional suppression of several class I antigen presentation genes. To systematically identify regulators of HLA-I loss in MCC, we performed parallel, genome-scale, gain- and loss-of-function screens in a patient-derived MCPyV-positive cell line and identified MYCL and the non-canonical Polycomb repressive complex 1.1 (PRC1.1) as HLA-I repressors. We observed physical interaction of MYCL with the MCPyV small T viral antigen, supporting a mechanism of virally mediated HLA-I suppression. We further identify the PRC1.1 component USP7 as a pharmacologic target to restore HLA-I expression in MCC.

Details

Language :
English
ISSN :
1558-8238
Volume :
132
Issue :
13
Database :
MEDLINE
Journal :
The Journal of clinical investigation
Publication Type :
Academic Journal
Accession number :
35775490
Full Text :
https://doi.org/10.1172/JCI151666